The uncovering of STAT3 as a target of SR141716 activity, which we believe is novel in cancer, constitutes the molecular bases of this dual activity enclosed in SR141716 molecule and highlight CB1-STAT3 as a potential new oncogenic axis in the complex glioma biology. This evidence concerns the gene STAT3 and central nervous system cancer.